Immediate Impact
61 standout
Citing Papers
Emerging Delivery Systems for Enabling Precision Nucleic Acid Therapeutics
2025 Standout
The present and future of bispecific antibodies for cancer therapy
2024 Standout
Works of Jason Aldred being referenced
Randomized phase I clinical trial of anti–α‐synuclein antibody BIIB054
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jason Aldred | 476 | 60 | 71 | 155 | 33 | 592 | |
| Han Kyu Na | 192 | 54 | 93 | 144 | 40 | 675 | |
| Sandro Zambito Marsala | 345 | 67 | 94 | 85 | 34 | 616 | |
| A Floyd | 367 | 62 | 36 | 134 | 28 | 643 | |
| R. De Notaris | 458 | 46 | 47 | 190 | 15 | 719 | |
| Adrienne M. Keener | 343 | 57 | 56 | 74 | 29 | 516 | |
| T Asser | 385 | 75 | 86 | 95 | 16 | 651 | |
| Corneliu Luca | 348 | 51 | 146 | 83 | 45 | 688 | |
| João Santos Pereira | 373 | 47 | 67 | 113 | 67 | 694 | |
| Stacey Kowal | 343 | 30 | 42 | 92 | 34 | 599 | |
| Chandler E. Gill | 423 | 19 | 70 | 167 | 39 | 529 |
All Works
Login with ORCID to disown or claim papers
Loading papers...